COMPANY
PIPELINE
R&D
IR
PR
CAREERS
Therapex Suggests Best-in-Class Potential for 'TRX-211-399' at AACR An..
│Shows improved selectivity and blood-brain barrier permeability compared to pre-existing competitorsKwangwoo Chun, PhD..
Therapex Launches Attack on Tagrisso-Resistant Lung Cancer with Target..
Approval of an Investigational New Drug application (IND) for the Phase 1/2 study of EGFR-TKI Resistant Non-Small Cell..
Therapex Unveils “Broad Spectrum” Strategy for Fourth-Generation Lung ..
Therapex has entered clinical trials to develop a fourth-generation drug for Epidermal Growth Factor Receptor (EGFR) mu..
Therapex Presents Poster on Anticancer Agent for Non-Small Cell Lung C..
Therapex CEO Koo Lee PhD (left) presenting the follow-up results of the preclinical study of the non-small cell lung ca..
Therapex Presents Preclinical Study Results of Non-Small Cell Lung Can..
Therapex, a subsidiary of Gradient, announced on October 10th that it will participate in the European Society for Med..
FDA Approves Therapex's Targeted Anti-Cancer Agent for Non-Small Cell ..
TRX-221's anti-tumor effect in EGFR C797S mutant non-small cell lung cancer patients to be confirmed in clinical trial..
Therapex's Innovative “Broad-Spectrum” Approach in EGFR-Targeted Antic..
Experienced anticancer drug development team leads clinical trials for broad-spectrum drug candidates targeting variou..
EGFR Lung Cancer Game Changer “Tagrisso”, In Development to Expand Ind..
EGFR Lung Cancer Game Changer "Tagrisso," In Development to Expand Indication to Early-Stage PatientsSource: ..
The Rapidly Emerging Platform, PROTAC, Known as the ‘Kiss of Death’ ..
Bioplus Interphex Korea (BIX) 2023 opened at COEX, Seoul from July 12th to July 14th Korea Bio Association and Ree..
"TRX-221" from Therapex Grabs the Attention of Global Cancer..
Preclinical results announced for the fourth-generation lung cancer drug candidate “TRX-221"Therapex, a Korean can..
